About BigHat Biosciences
BigHat Biosciences is a Series B biotechnology company that develops next-generation antibody therapeutics using an integrated machine learning and synthetic biology platform. Founded in 2019 and headquartered in San Mateo, California, the company has raised over $100 million from top investors to pursue its mission of creating safer, more effective antibody therapies for patients. The company's proprietary Milliner platform combines a synthetic biology-based high-speed wet lab with state-of-the-art machine learning technologies into a full-stack antibody discovery and engineering system. At the heart of this platform is Reccy Antibody Design Studio (RADS), an AI-driven system that orchestrates thousands of models and datasets through continuous design-build-test cycles. The platform can synthesize, purify, and fully characterize hundreds of recombinant antibodies for biophysics and function in a single weekly workcell, dramatically accelerating the path from hypothesis to development candidate. BigHat's technology addresses the complex challenges of antibody therapeutic development, including affinity, specificity, stability, manufacturability, and immunogenicity. The company applies its capabilities to both wholly-owned therapeutic programs and strategic partnerships with leading pharmaceutical companies including Eli Lilly, Johnson & Johnson, and Lonza's Synaffix. By leveraging cell-free protein synthesis, automated assays, and iterative machine learning optimization, BigHat is advancing treatments for today's most challenging diseases, from inflammation and infections to cancers.
Mission & Story
Mission
BigHat Biosciences designs safer, more effective antibody therapies for patients using machine learning and synthetic biology
Founding Story
Founded in 2019 with co-founder and CSO Peyton Greenside leading the scientific vision. The company was established to overcome the limitations of conventional antibody engineering by integrating AI-driven design with high-throughput synthetic biology.
Clinical Focus
Medical conditions and clinical areas addressed by BigHat Biosciences.
Who It Serves
Milestones & Awards
Recent Milestones
Appointed Stefan Weigand as Chief Scientific Officer (June 2026); Launched Reccy Antibody Design Studio/RADS (September 2025); Partnership with Lilly for ML-enabled biologics discovery (January 2026, April 2025); Completed J&J strategic collaboration (October 2025); Lonza Synaffix ADC collaboration (November 2024)
Awards & Recognition
Featured in Genetic Engineering & Biotechnology News (August 2024)
Key Partnerships
Company Details
- Founded
- 2019
- Headquarters
- San Mateo, CA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.